Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Adult
Aged
Aged, 80 and over
Albumins
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Neoplasms
/ drug therapy
Brain Neoplasms
/ drug therapy
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Drug Combinations
Female
Follow-Up Studies
Humans
Liver Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Lymphatic Metastasis
Maintenance Chemotherapy
Male
Middle Aged
Nanoparticles
Oxonic Acid
/ administration & dosage
Paclitaxel
/ administration & dosage
Prognosis
Survival Rate
Tegafur
/ administration & dosage
Carboplatin
Lung squamous cell carcinoma
Maintenance therapy
S-1
nab-paclitaxel
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
17
01
2019
accepted:
12
02
2019
pubmed:
23
2
2019
medline:
23
2
2020
entrez:
22
2
2019
Statut:
ppublish
Résumé
Background Optimal maintenance therapy for lung squamous cell carcinoma (SCC) has not been established. The aim of this study was to evaluate the efficacy and safety of switch maintenance therapy with S-1, an oral fluoropyrimidine, after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in chemotherapy-naïve patients with advanced SCC. Methods Chemotherapy-naïve patients with advanced SCC received induction therapy with four cycles of carboplatin (at an area under the curve of 6, day 1 of a 28-day cycle) and nab-paclitaxel (100 mg/kg, days 1, 8, and 15). Patients who achieved disease control after induction therapy received maintenance therapy with S-1 (80 mg/m
Identifiants
pubmed: 30790149
doi: 10.1007/s10637-019-00747-x
pii: 10.1007/s10637-019-00747-x
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-537Références
Ann Oncol. 2015 Jul;26(7):1401-8
pubmed: 25908605
J Thorac Oncol. 2011 Feb;6(2):365-71
pubmed: 21173713
Ann Oncol. 2016 Jul;27(7):1266-72
pubmed: 27056996
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Cancer Chemother Pharmacol. 2012 Apr;69(4):1005-11
pubmed: 22160350
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
Thorax. 2004 Aug;59(8):679-81
pubmed: 15282388
Lung Cancer. 2017 Jun;108:66-71
pubmed: 28625650
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Clin Oncol. 2013 Aug 20;31(24):3004-11
pubmed: 23835708
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Invest New Drugs. 2016 Aug;34(4):490-6
pubmed: 27279143
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Lung Cancer. 1998 Aug;21(2):105-13
pubmed: 9829544
J Clin Oncol. 2013 Aug 10;31(23):2895-902
pubmed: 23835707
Invest New Drugs. 2018 Oct;36(5):903-910
pubmed: 29846848
Ann Oncol. 2013 May;24(5):1326-31
pubmed: 23277482
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
Lung Cancer. 2011 Oct;74(1):85-8
pubmed: 21342712
J Clin Oncol. 2017 Oct 20;35(30):3484-3515
pubmed: 28806116
Ann Oncol. 2017 Nov 1;28(11):2698-2706
pubmed: 29045553
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
J Thorac Oncol. 2010 Apr;5(4):540-5
pubmed: 20195170
Lancet. 2016 Jul 16;388(10041):248-57
pubmed: 27265347
J Clin Oncol. 2010 Dec 20;28(36):5240-6
pubmed: 21079147
Lancet Oncol. 2010 Jun;11(6):521-9
pubmed: 20493771
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Lancet. 2009 Oct 24;374(9699):1432-40
pubmed: 19767093
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Thorac Oncol. 2016 Sep;11(9):1411-22
pubmed: 27296106
Mol Cancer Ther. 2008 Dec;7(12):3670-84
pubmed: 19074844
Nat Rev Drug Discov. 2004 May;3(5):391-400
pubmed: 15136787